Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Controlled Trial

P180613

The purpose of this study is to determine whether itacitinib is safe and effective in the treatment of systemic sclerosis in adults.

2023-02-02

2026-02-01

2026-02-01

Recruiting

Early phase I

74

Inclusion Criteria: * Adult patient (≥18 years old) * Patient with a diagnosis of diffuse SSc, as defined by the American College of Rheumatology / EULAR 2013 criteria, * Patient with a SSc disease duration of less than 36 months (defined as time from first non-Raynaud phenomenon manifestation) or with an active SSc disease, as defined by EUSTAR disease activity score, * Patient with a modified Rodnan skin score (mRSS) ≥ 10 and ≤ 35 units at screening, * Negative pregnancy test for woman of childbearing potential, woman of childbearing potential should have reliable contraception for the 12 months' duration of the study, * Patient able to give written informed consent prior to participation in the study, * Affiliation to a social security scheme (profit or being entitled). Exclusion Criteria: * Previous treatment with itacitinib or a Janus kinase (JAK) inhibitor, * Contra-indications to itacitinib or Janus kinase inhibitor, * Failure to sign the informed consent or unable to consent * Patient participating in another investigational therapeutic study, * Acute or chronic active infections, including HBV, HCV, HIV, * Patient with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol, * Patient suspected not to be observant to the proposed treatments, * Patient who have white blood cell count ≤ 4,000/mm3, * Patient who have platelet count ≤ 100,000/mm3, * Patients who have ALT or AST level greater that 3 times the upper limit of normal, * Patient who have triglyceride level greater than 5g/L * Pregnant or breastfeeding woman, * Protected adults (including individual under guardianship by court order), * Patient receiving or having received cyclophosphamide or rituximab within the last three months (possible inclusion beyond 3 months), * Patient receiving or having received a biotherapy (anti-TNF, abatacept or tocilizumab) in the last 3 months (possible inclusion beyond 3 months) * Atherosclerotic cardiovascular disease as defined by a history of myocardial infarction, ischaemic stroke, or peripheral artery thrombosis * Anti-phospholipid syndrome

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 74, 'type': 'ESTIMATED'}}

2024-05-31